This animal model study demonstrates that Ac-SDKP, a tetrapeptide fragment derived from thymosin beta-4, reduces fibrosis in silica-induced lung injury by modulating apoptosis through HSP27 and the FAS/FASL and mitochondrial signaling pathways. The research clarifies specific molecular mechanisms of action for this anti-fibrotic compound in occupational lung disease. The findings support Ac-SDKP’s therapeutic potential for practitioners treating silicosis and other progressive fibrotic lung conditions.
For your business
Ac-SDKP may reduce fibrotic progression via HSP27 and apoptotic pathways, relevant when considering options for silicosis-related lung fibrosis.